SMTI Sanara MedTech
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
Company profile
Ticker
SMTI
Exchange
Website
CEO
J. Michael Carmena
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INAV TRAVEL CORPORATION, MB SOFTWARE CORP, WOUND MANAGEMENT TECHNOLOGIES, INC.
SEC CIK
Corporate docs
IRS number
592220004
SMTI stock data
()
News
12 Health Care Stocks Moving In Monday's Intraday Session
15 Mar 21
64 Biggest Movers From Friday
16 Feb 21
12 Health Care Stocks Moving In Friday's Intraday Session
12 Feb 21
30 Stocks Moving In Friday's Mid-Day Session
12 Feb 21
Mid-Morning Market Update: US Stock Futures Trend Down; Nasdaq Composite Dips 0.2%
12 Feb 21
Press releases
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2020 Results
31 Mar 21
Sanara MedTech Inc. Announces Closing of $31.6 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
17 Feb 21
Sanara MedTech Inc. Announces Pricing of Public Offering
12 Feb 21
Sanara MedTech Inc. Announces Proposed Public Offering of Common Stock
11 Feb 21
Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020
25 Jan 21
Investment data
Securities sold
Number of investors
Calendar
29 Mar 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 455.37K | 455.37K | 455.37K | 455.37K | 455.37K | 455.37K |
Cash burn (monthly) | 554.96K | 513.05K | 284.02K | 419.55K | 197.02K | 336.21K |
Cash used (since last report) | 2.01M | 1.86M | 1.03M | 1.52M | 712.84K | 1.22M |
Cash remaining | -1.55M | -1.4M | -572.23K | -1.06M | -257.48K | -761.06K |
Runway (months of cash) | -2.8 | -2.7 | -2.0 | -2.5 | -1.3 | -2.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep 20 | Michael D. McNeil | Common Stock | Grant | Aquire A | No | No | 0 | 1,247 | 0 | 11,884 |
30 Sep 20 | Fleming Zachary B. | Common Stock | Grant | Aquire A | No | No | 0 | 1,603 | 0 | 19,708 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
1.4% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 16 |
Opened positions | 16 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 5.2M |
Total shares | 104.65K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 59.2K | $2.95M |
Millennium Management | 10.54K | $526K |
ExodusPoint Capital Management | 10.32K | $515K |
Diametric Capital | 5.71K | $285K |
Arete Wealth Management | 5.4K | $247K |
CCG Wealth Management | 5.4K | $269K |
Smart Money | 5K | $250K |
C Citigroup | 1.7K | $85K |
Lee Financial | 500 | $25K |
UBS UBS Group AG - Registered Shares | 369 | $18K |
Financial report summary
?Risks
- Risks Related to How We Operate Our Business
- The COVID-19 pandemic in the United States has and may continue to negatively impact our business, financial condition and results of operations.
- We have had a history of losses, which may continue as we expand our selling efforts.
- Our revenue growth for a particular period is difficult to predict, and a shortfall in forecast revenues may harm our operating results.
- Our current comprehensive wound and skin care strategy involves growth through acquisitions and investments, which requires us to incur substantial costs and potential liabilities for which we may never realize the anticipated benefits.
- If we cannot meet our future capital requirements, our business will suffer.
- Failure to retain and recruit key personnel would harm our ability to meet key objectives.
- We operate in highly competitive markets and face competition from large, well-established medical device manufacturers and telehealth providers as well as new market entrants, and if we are unable to compete within our markets or our products and services do not gain market acceptance, our operating results and financial condition could suffer.
- Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.
- If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.
- The Loan Agreement governing our revolving line of credit includes restrictive terms, and our failure to comply with any of these terms could result in a default, which would have an adverse effect on our business and prospects.
- Risks Related to Our Products
- We rely on our research and development partners to design, manufacture and supply the products we have licensed for marketing. If one of our partners fails to perform adequately or fulfill our needs, we may be required to incur significant costs. We may also face significant delays in our product introductions and commercialization.
- Our future success will largely depend on our ability to maintain and further grow clinical acceptance and adoption of our products, and we may be unable to adequately educate healthcare practitioners on the use and benefits of our products.
- Competitors could invent products superior to ours and cause our products and technologies to become obsolete.
- Disruption of, or changes in, our distribution model or customer base could harm our sales and margins.
- If we are unable to manage product inventory in an effective and efficient manner, our profitability could be impaired.
- Failure of any third-party assessments to demonstrate desired outcomes in proposed endpoints may result in adverse regulatory actions, reduce physician usage or adoption of our products, or reduce the price, coverage and/or reimbursement for our products, which could have a negative impact on our business performance.
- We may have exposure to product liability claims.
- Interruptions in the supply of our products or inventory loss may adversely affect our business, results of operations and financial condition.
- Increased prices for, or unavailability of, raw materials used in our products could adversely affect our business, results of operations and financial condition.
- Risks Related to Our Planned Expansion into Wound and Skin Care Virtual Consult and Other Services
- Our planned expansion into wound and skin care virtual consult and other services could have a material adverse effect on our business, financial condition or results of operations.
- Our planned expansion into wound and skin care virtual consult and other services will require entrance into several markets in which we have little or no experience, which may not be successful and could be costly.
- Our planned expansion into the telehealth business is dependent on our relationships with affiliated professional entities to provide physician services, and our business would be adversely affected if those relationships were disrupted.
- Recent and frequent state legislative and regulatory changes specific to telemedicine may present us with additional requirements and state compliance costs, with potential operational impacts in certain jurisdictions.
- Risks Related to Intellectual Property
- If we are unable to adequately protect our intellectual property rights, we may not be able to compete effectively.
- CellerateRX Surgical is not currently protected by any pending patent application nor any unexpired patent. Accordingly, CellerateRX Surgical may be subject to competition from the sale of substantially equivalent products that could adversely affect our business and operations.
- We are heavily dependent on technologies and products we have licensed from third parties, and we may need to license technologies and products in the future, and if we fail to obtain licenses we need, or fail to comply with our payment obligations in the agreements under which we in-license intellectual property and other rights from third parties, we could lose our ability to develop and commercialize our products.
- We may be found to infringe on intellectual property rights of others.
- Risks Related to Regulations
- Our business is affected by numerous regulations relating to the labeling, marketing and sale of our products.
- If we fail to obtain or experience significant delays in obtaining regulatory clearances or approvals to market future medical device products, we will be unable to commercialize these products until such clearance or approval is obtained.
- Changes to the FDA clearance and approval processes or ongoing regulatory requirements could make it more difficult for us to obtain FDA clearance or approval of new products or comply with ongoing requirements.
- Modifications to our current products may require new marketing clearances or approvals or require us to cease marketing or recall the modified products until such clearances or approvals are obtained.
- Failure to obtain or maintain adequate reimbursement or insurance coverage for drugs, if any, could limit our ability to market those drugs and decrease our ability to generate revenue. Changes in reimbursement policies and regulations by governmental or other third-party payors may have an adverse impact on the use of our products.
- We rely on our research and development partners to comply with applicable laws and regulations relating to product classification and FDA marketing authorization.
- We and our employees and contractors are subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse laws, including false claims laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Our research and development partners’ use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, business, financial condition and results of operations.
- Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.
- If we fail to comply with extensive healthcare laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.
- Our officers, employees, independent contractors, principal investigators, consultants, and commercial partners may engage in misconduct or activities that are improper under other laws and regulations, which would create liability for us.
- We could be adversely affected if healthcare reform measures substantially change the market for medical care or healthcare coverage in the United States.
- Defects, failures or quality issues associated with our products could lead to product recalls or safety alerts, adverse regulatory actions, litigation and negative publicity that could materially adversely affect our reputation, business, results of operations and financial condition.
- Risks Related to Ownership of Our Common Stock
- The issuance of shares upon the exercise of derivative securities may cause immediate and substantial dilution to our existing shareholders.
- It is possible that we will require additional capital to meet our financial obligations and support business growth.
- The trading price of the shares of our common stock is highly volatile, and purchasers of our common stock could incur substantial losses.
- Our common stock does not have a vigorous trading market, and you may not be able to sell your securities at or near ask prices, or at all.
- The potential sale of large amounts of common stock may have a negative effect upon the market value of our shares.
- We have not paid, and we are unlikely to pay, cash dividends on our securities in the near future. Because we have no current plans to pay cash dividends on our common stock for the foreseeable future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.
- A few of our existing shareholders own a large percentage of our voting stock and have control over matters requiring shareholder approval and may delay or prevent a change in control or otherwise lead to actual or potential conflicts of interest.
- Our Certificate of Formation includes provisions limiting the personal liability of our directors for breaches of fiduciary duties under Texas law.
- Texas law and our Certificate of Formation and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that shareholders may consider favorable.
- Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.
Management Discussion
- Revenues. For the year ended December 31, 2020, we generated revenues of $15,586,976 compared to revenues of $11,766,763 for the year ended December 31, 2019, a 32% increase from the prior year. The higher revenues in 2020 were primarily due to increased sales of surgical wound care products as we continued the execution of our strategy to expand our sales force and independent distribution network in both new and existing U.S. markets.
- Beginning in March 2020, many states issued orders suspending elective surgeries in order to free-up hospital resources to treat COVID-19 patients. This resulted in a reduction in demand for our surgical products beginning in the second half of March 2020. Additionally, most states limited access to SNFs to only resident caregivers, which impeded our ability to provide education and product training to the clinicians who use our products in these facilities. These restrictions resulted in an overall decline in sales for the second quarter of 2020.
- During the third and fourth quarters of 2020, we saw a strong rebound in product sales as restrictions on elective surgeries eased in our primary markets in Texas, Florida, and the southeastern United States. Fourth quarter revenues of $4,789,138 were up 43% compared to the fourth quarter of 2019, and represented a record high sales quarter for the Company.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AB, abbreviated, aberrant, abide, ACA, accuracy, accurate, accurately, acid, adequacy, adhere, adherence, administer, administered, administering, admitting, adulterated, advice, advisor, advisory, advocate, agency, aid, aiding, aim, allegedly, allergic, alter, Alto, amino, amnion, amniotic, amputation, analyze, analyzed, anatomy, Android, ankle, anniversary, anonymously, antitrust, app, Apple, arriving, article, Atterase, auto, autolytic, avoid, avoiding, back, backlash, beauty, beneficiary, Biden, bioassay, biochemical, biocompatible, biologic, biological, Biology, Biotech, Bipartisan, Bldg, Blvd, bony, bore, bottle, bottom, Bradley, breadth, bribe, broader, broadly, brokerage, budget, burden, burdensome, buy, caesarean, calf, California, Cantor, cap, Capture, captured, cardiothoracic, caregiver, Carlson, carryforward, categorized, caution, Cautionary, CBER, cCTP, CDRH, cellular, Center, central, certiorari, cGMP, cGTP, champion, chance, Chapter, choice, choose, chosen, Christopher, chronification, Circuit, circumscribe, classified, classify, clause, client, climate, closure, clot, Cockrell, codified, coiled, collaboration, collagenase, colorectal, column, comfortable, commerce, compel, compelling, complaint, complicating, complication, component, comprehensive, concealing, confidentiality, confidentially, configuration, confined, congressional, consequential, Constant, constantly, continuum, contributor, ConvaTec, convince, convincing, Cook, correction, corrective, Corstrata, covertly, cranioplasty, creation, CRO, crucial, currency, cushion, custody, cybersecurity, dampen, Darden, Database, de, debarment, deceive, decellularize, deceptive, deepen, deeper, defraud, degraded, dehiscence, delist, delisting, denying, deploy, deploying, dermatology, DeSutter, detaining, detention, deviate, devote, diagnosing, diagnostic, dialogue, difficulty, digital, DirectDerm, disciplinary, discourage, discouraged, discovery, discretionary, disgorgement, disinfect, dissemination, Doctorate, doctrine, dominated, downstream, draft, drafted, draining, dramatically, drawn, driver, duty, dwell, eased, ECM, effort, elderly, embezzling, empowered, EMR, enable, enabled, Enclave, endeavor, energy, enrollment, entrance, environment, environmental, erode, essential, ethical, etiology, etiquette, excessive, exorbitant, expend, export, expressly, Exxon, ExxonMobil, faith, falsifying, fashion, favorable, favorably, FCA, FDASIA, FDCA, fiduciary, Fitzgerald, Florida, FLOWABLE, fluid, flux, footprint, forgiven, formulary, formulation, FORTIFY, Fortune, fraudulent, friction, friendly, FTC, fuel, fullest, fundamental, gather, good, gram, granulation, graphic, greatly, GUDID, Gurasich, gynecologic, gynecology, half, halt, harbor, head, heart, heavily, heightened, helical, helix, hesitant, HHS, hip, HIPAA, honest, hospice, hostile, hour, hydrated, hydrogel, hydrolysate, HyperMed, hypertension, IDE, imagery, imaging, implicate, imprisonment, improper, improperly, impropriety, inaccurate, inactive, inappropriate, inappropriately, incision, inclusion, increasingly, Index, ineffectively, inflammation, inflammatory, inflation, injunction, injunctive, injury, inpatient, inside, insight, insoluble, installation, instance, Intellicure, interfaced, interfere, interfering, interim, interoperability, interruption, intervene, intervention, intestinal, introduction, invaluable, IRB, irregular, irrespective, Irving, jeopardized, job, jurisdiction, Justice, Kent, kickback, kind, knee, knowingly, labor, language, lawsuit, lay, layer, learning, leave, left, Lender, lessening, lesser, leverage, liable, licensor, licensure, light, load, log, logo, loyalty, LTIP, Lumicell, magnitude, malfunctioned, mandate, mandated, mandatory, margin, match, matching, matrix, media, membrane, mgroup, migration, minimal, minimally, minimize, Minnesota, misbranded, misconduct, misuse, misused, misusing, mitigate, mitigating, mixture, mobile, modality, moisture, molecule, MolecuLight, Morrison, mortality, motivate, mounted, MRSA, multispecialty, mutual, Narrative, narrow, narrowly, navigate, necessity, neck, negligence, negligent, negotiate, negotiation, NetHealth, neurosurgery, NOL, nonhealing, novo, Obama, obstructing, omission, oncology, online, ophthalmic, opposed, organizational, ortho, Ortwein, overestimate, overheat, overpayment, overtly, packing, pad, page, Palo, pandemic, park, Parkway, passed, path, Paycheck, payer, payor, pediatric, penalty, penetrating, penetration, people, perimeter, permissible, persistent, phase, PHI, photo, PHSA, physical, PII, Piper, platform, play, podiatric, post, PPP, precaution, Precision, predominance, preempted, preliminary, prepay, prescribed, prescribing, prevailing, problematic, proceed, proceeding, procurement, profile, proliferation, prolonged, prompt, promulgated, proof, proper, prosecute, prosecution, protocol, published, pump, puncture, purity, push, QSR, quality, quantify, qui, Radiological, rapidly, reaction, readmission, real, rebate, rebound, recipient, reclassification, recordkeeping, recur, recurring, reelection, refinance, refinancing, rehabilitative, reinforce, reject, relaunch, relief, relieve, remanded, repeal, repealed, rescission, resident, Resolution, rest, restore, resumed, retention, reward, Rialto, rigidly, rigorously, roughly, RSM, run, running, salesforce, SanaraU, Sandler, Sara, satisfactory, scale, scheme, scientific, SciMedCentral, scrutinize, se, segment, seizing, senescent, sensation, seventeen, shear, shelf, shift, shutdown, Similarly, simple, simultaneously, SIS, slate, smart, smoking, Society, soft, soluble, southeastern, speaker, SpectralMD, spending, sporting, spread, statistically, stealing, stemming, sterile, sterilized, storage, strength, strict, stricter, strictly, stringent, strive, stronger, Subchapter, Sublicensee, sublicensor, submucosa, suboptimal, subregulatory, subsidize, substantive, sue, sued, suggesting, sunshine, supplier, Supreme, surveillance, surviving, suspected, suspended, suspending, sweep, Swift, tailbone, tam, Tangible, teach, teaching, teledermatology, telehealth, telemedicine, temperature, texting, theft, therapeutic, thereto, thereunder, thin, thousand, threatened, toiletry, tool, track, tracked, tracking, traditional, trajectory, transformative, transmit, transparency, transplantation, transported, trend, TRG, trick, trouble, true, Trump, truthful, turn, UDI, ulcer, unapproved, unauthorized, unavailability, unconstitutional, unconventional, underestimate, undergoing, understated, undertaken, underway, underwritten, undetected, unexpected, unfair, unfamiliar, unintentional, unissued, unlawful, unlicensed, unprecedented, unreasonable, unsatisfactory, unscheduled, unsuitable, untitled, unused, upstream, urologic, urology, usage, VAC, valid, validation, validity, valuable, Vancomycin, vasculature, vertical, vigilance, VIM, virtual, virtually, vision, Vohra, waive, warning, waste, weaken, weather, web, whistleblower, widespread, willfully, workforce, WounDerm, WoundTech, Woundyne, wrongful, XTO, yearly
Removed:
accreted, accruing, Acelity, Adjuvant, allocating, ban, BCF, cancellation, capable, carefully, challenge, Colorado, conform, constrained, contingent, contractor, credentialed, credibility, dental, Diane, eAppliance, embedded, emerged, employed, excise, existed, expired, feature, forfeiture, formal, fraction, fulfilled, fulfilling, funded, furniture, highlight, inducement, inhibit, intrinsic, involvement, John, Lindsey, MB, merged, noncompliance, omitted, organized, OTC, painting, phone, PHS, plastic, podiatry, preemptive, prepaid, principle, produce, prohibited, pronouncement, reconstructive, redemption, reliance, removed, renovation, replacing, resigned, restructured, retroactive, short, Siedhoff, sinking, solicitation, structured, targeted, thereon, Twin, TX, undue, unpaid, vendor, view, WCI, Wilson, word
Financial reports
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
13 Nov 20
10-Q
2020 Q2
Quarterly report
13 Aug 20
10-Q
2020 Q1
Quarterly report
12 May 20
10-K
2019 FY
Annual report
26 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
20 May 19
NT 10-Q
Notice of late quarterly filing
16 May 19
10-K
2018 FY
Annual report
1 Apr 19
Current reports
8-K
Regulation FD Disclosure
23 Feb 21
8-K
Sanara MedTech Inc. Announces Proposed Public Offering of Common Stock
17 Feb 21
8-K
Entry into a Material Definitive Agreement
1 Feb 21
8-K
Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020
25 Jan 21
8-K
Entry into a Material Definitive Agreement
22 Jan 21
8-K
Departure of Directors or Certain Officers
23 Dec 20
8-K
Regulation FD Disclosure
29 Oct 20
8-K
Sanara MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board of Directors
16 Oct 20
8-K/A
Submission of Matters to a Vote of Security Holders
14 Oct 20
8-K
Departure of Directors or Certain Officers
14 Jul 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Feb 21
424B5
Prospectus supplement for primary offering
11 Feb 21
D
$1.07M in equity, sold $1.07M, 2 investors
25 Jan 21
S-3
Shelf registration
23 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 20
8-A12B
Registration of securities on exchange
29 Oct 20
S-8
Registration of securities for employees
21 Feb 20
RW
Registration withdrawal request
13 Jan 09
S-1/A
IPO registration (amended)
9 Jun 08
S-1
IPO registration
10 Apr 08
Proxies
DEF 14A
Definitive proxy
25 Jun 20
DEF 14C
Information statement
3 Apr 19
PRE 14C
Preliminary information
22 Mar 19
DEF 14A
Definitive proxy
20 Jul 14
DEFA14A
Additional proxy soliciting materials
20 Jul 14
PRER14A
Preliminary revised proxy
1 Jul 14
PRE 14A
Preliminary proxy
5 Jun 14
DEF 14C
Information statement
12 May 08
PRE 14C
Preliminary information
24 Apr 08
DEF 14C
Information statement
25 Jul 02
Other
EFFECT
Notice of effectiveness
5 Jan 21
CORRESP
Correspondence with SEC
29 Dec 20
UPLOAD
Letter from SEC
29 Dec 20
UPLOAD
Letter from SEC
6 Jul 14
CORRESP
Correspondence with SEC
30 Jun 14
UPLOAD
Letter from SEC
24 Jun 14
UPLOAD
Letter from SEC
20 Oct 10
UPLOAD
Letter from SEC
18 Oct 10
UPLOAD
Letter from SEC
18 Oct 10
CORRESP
Correspondence with SEC
30 Sep 10
Ownership
3
Sanara MedTech / Christopher A. Morrison ownership change
17 Feb 21
3
Sanara MedTech / Sara N Ortwein ownership change
28 Dec 20
3
Sanara MedTech / Robert Andrew DeSutter ownership change
21 Oct 20
4
Sanara MedTech / J Michael Carmena ownership change
2 Oct 20
4
Sanara MedTech / Shawn M. Bowman ownership change
2 Oct 20
4
Sanara MedTech / Zachary B. Fleming ownership change
2 Oct 20
4
Sanara MedTech / Michael D. McNeil ownership change
2 Oct 20
4
Sanara MedTech / Shawn M. Bowman ownership change
29 Apr 20
3/A
Sanara MedTech / Zachary B. Fleming ownership change
29 Apr 20
4
Sanara MedTech / Shawn M. Bowman ownership change
26 Feb 20
Reddit threads
Daily Discussion Thread - April 1st, 2021
1 Apr 21
Daily Discussion Thread - March 31st, 2021
31 Mar 21
Daily Discussion Thread - March 25th, 2021
25 Mar 21
Daily Discussion Thread - March 24th, 2021
24 Mar 21
Daily Discussion Thread - March 23rd, 2021
23 Mar 21
Daily Discussion Thread - March 22nd, 2021
22 Mar 21
Daily Discussion Thread - November 12th, 2020
12 Nov 20
Daily Discussion Thread - November 11th, 2020
11 Nov 20
Daily Discussion Thread - November 10th, 2020
10 Nov 20
Daily Discussion Thread - November 9th, 2020
9 Nov 20